論文

1) Yoshiro Abe, Masahiko Tanaka. Concentration of ethyl icosapentaenoate from Japanese sardine oil by molecular sieve column. Fette Seifen Anstrichmittel 1984; 86: 8-10. Wiley Online Library
2) 柴田久雄, 新井重紀, 井澤美苗, 村崎光邦, 高松康雄, 井澤修, 高橋千寿子, 田中正彦. MCI-186（Edaravone）の第Ⅰ相臨床試験: 単回および反復投与試験における安全性と薬物動態の検討. 臨床薬理 1998; 29: 863-876. J-STAGE
3) Kazutoshi Watanabe, Yasuhiro Morinaka, Yoshio Hayashi, Masaki Shinoda, Hiroyoshi Nishi, Nobuko Fukushima, Toshiaki Watanabe, Akira Ishibashi, Satoshi Yuki, Masahiko Tanaka. 5-Aryl-imidazolin-2-ones as a scaffold for potent antioxidant and memory-improving activity. Bioorg Med Chem Lett 2008; 18: 1478-1483. ScienceDirect
4) Yorihiro Yamamoto, Makoto Yanagisawa, Nyou Wei Tak, Kazutoshi Watanabe, Chizuko Takahashi, Akio Fujisawa, Misato Kashiba, Masahiko Tanaka. Repeated edaravone treatment reduces oxidative cell damage in rat brain induced by middle cerebral artery occlusion. Redox Rep 2009; 14: 251-258. Taylor & Francis Online
5) The Writing Group* on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised,double-blind, placebo-controlled trial. Lancet Neurol 2017; 16: 505-512. *Edaravone (MCI-186) ALS 19 Study Writing Group: Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino. The Lancet Neurology
6) Koji Abe, Yasuto Itoyama, Shoji Tsuji, Gen Sobue, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Masanori Togo, Takatomo Yoneoka, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino: A post-hoc subgroup analysis of outcomes in the first phase 3 clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 11-19. Taylor & Francis Online
7) The Writing Group* on behalf of the Edaravone (MCI-186) ALS 17 Study Group: Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 20-31. *Edaravone (MCI-186) ALS 17 Study Writing Group: Koji Abe, Yasuto Itoyama, Shoji Tsuji, Gen Sobue, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Hiroshi Naito, Aiko Murakami, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino. Taylor & Francis Online
8) The Writing Group* on behalf of the Edaravone (MCI-186) ALS 18 Study Group: Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 40-48. *Edaravone (MCI-186) ALS 18 Study Writing Group: Koji Abe, Yasuto Itoyama, Shoji Tsuji, Gen Sobue, Masashi Aoki, Manabu Doyu, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Rie Sumii, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino. Taylor & Francis Online
9) The Writing Group* on behalf of the Edaravone (MCI-186) ALS 19 Study Group: Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 55-63. *Edaravone (MCI-186) ALS 19 Study Writing Group: Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Masaki Ueda, Kazuoki Kondo, Hiide Yoshino. Taylor & Francis Online
10) Masahiko Tanaka, Natsuhiko Sugimura, Akio Fujisawa, Yorihiro Yamamoto. Stabilizers of edaravone aqueous solution and their action mechanisms. 1. Sodium bisulfite. J Clin Biochem Nutr, 2017; 61: 159-163. J-STAGE
11) Masahiko Tanaka, Satsuki Motomiya, Akio Fujisawa, Yorihiro Yamamoto. Stabilizers of edaravone aqueous solution and their action mechanisms. 2. Glutathione. J Clin Biochem Nutr, 2017; 61: 164-168. J-STAGE
1) 田中正彦. 脳保護薬（フリーラジカルスカベンジャー）エダラボン（ラジカット注30mg）の非臨床および臨床プロフィール. 日薬理誌 2002; 119: 301-308. J-STAGE
2) 田中正彦. フリーラジカルスカベンジャー エダラボン: 脳保護薬へのアプローチ. Medchem News 2003; 13: 13-17.
3) 渡邉和俊, 田中正彦. 新規脳保護剤エダラボンの化学的, 薬理的及び臨床的プロファイル. 応用薬理 2003; 65: 79-88. CiNii
4) 渡辺俊明,田中正彦, 渡邉和俊, 高松康雄, 戸部昭広. 脳保護剤（フリーラジカル消去剤）エダラボンの研究開発. Yakugaku Zasshi 2004; 124: 99-111. J-STAGE 国立国会図書館デジタルコレクション
5) Kazutoshi Watanabe, Masahiko Tanaka, Satoshi Yuki, Manabu Hirai, Yorihiro Yamamoto. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr 2018; 62: 20-38. J-STAGE
1) 池田雅晴, 石塚秀実, 佐藤正章, 関根實, 武田ひとみ, 田中正彦, 東尾尚宏, 横川直躬. 脳卒中の評価と評価尺度に関する批判的検討. 薬理と治療 1993; 21: 657-667. メディカルオンライン
1) 田中正彦, 幸敏志. 急性期治療薬アルガトロバン, エダラボンの研究開発. Bioclinica 2005; 20: 899-903.
2) 田中正彦, 幸敏志. 脳血栓症/脳梗塞急性期治療薬アルガトロバン, エダラボンの研究開発. Bioclinica 2008; 23: 939-943.
3) 田中正彦. 脳保護薬（フリーラジカルスカベンジャー）エダラボンのプロフィル. Medical Science Digest 2008; 34: 419-421.
1) 田中正彦. エダラボン水溶液の安定化剤とその作用機序. 東京工科大学 2017; 東京工科大学 国立国会図書館デジタルコレクション